NEW YORK (GenomeWeb) – Cepheid is collaborating with AstraZeneca, Cubist Pharmaceuticals, and GlaxoSmithKline to develop a rapid diagnostic test that can analyze multi-drug resistant pathogens and help doctors prescribe the most beneficial antibiotics for patients.

Cepheid is currently developing the Xpert Carba-R test for assessing bacteria from rectal swab samples. The goal of the consortium is to enable the test to also analyze a variety of other biological samples, such as respiratory samples from pneumonia patients.

Get the full story

This story is free
for registered users

Registering provides access to this and other free content.

Register now.

Already have an account?
Login Now.

In Nature this week: association between genome-wide homozygosity and traits like height and cognitive ability, improved CRISPR-Cas9 editing, and more.

A survey examines how age, political leanings, and more influence how Americans view certain scientific topics, the Associated Press reports.

A researcher who pleaded guilty to making false statements in research reports has been sentenced to four and a half years in prison and must pay $7.2 million back to the NIH.

The BabySeq project to study the risks and benefits of sequencing newborns is underway.